AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
- Booth no. D200
At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those living with cancer begins with a very considered step forwards. Whether it’s from finding novel solution, a new indication approval, or even just reaching one more patient. That’s The Power of Purpose™.
- Booth no. D225
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.
- Booth no. D300
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies and has reached millions of patients globally.
- Booth no. D301
Eli Lilly and Company
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.
Daiichi Sankyo Europe GmbH
With more than 100 years of scientific expertise Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology. In addition to our portfolio of medicines for cancer and cardiovascular disease, we are focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs.
- Booth no. D220
Eisai Co., Ltd
Eisai’s human health care (hhc) Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” We strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in strategic areas of Neurology and Oncology.
- Booth no. D321
Mirati Therapeutics, Inc.
Mirati Therapeutics, is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
- Booth no. D100
Pfizer Oncology is committed to advancing medicines wherever we believe we can make a difference for people living with cancer. We have an industry-leading portfolio of 24 approved cancer medicines & biosimilars across 30+ indications—and are focused on delivering breakthroughs in breast and genitourinary cancer, hematology and precision medicine.
- Booth no. D320
Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer.
- Booth no. 325
PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. PharmaMar develops and commercializes Yondelis® in Europe. PharmaMar is also developing lurbinectedin in SCLC. It has been approved in 8 countries, following the US FDA accelerated approval for the treatment of metastatic SCLC.
- Booth no. 322
Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.
- Booth no. D350